KALAHARI: Part A Results of the Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor, in Subjects with DME who Respond Suboptimally to anti-VEGF Treatment

Shree K. Kurup, MD

Director, Surgical Ocular Immunology & Uveitis / Vitreoretinal Diseases, University Hospitals Cleveland Medical Center

Professor, Case Western Reserve University School of Medicine

Coauthors

David J. Warrow, MD; Joel A. Pearlman, MD PhD; Rahul N. Khurana, MD; Lawrence J. Singerman, MD & David S. Boyer, MD